Total Payments
$2,598
2024 Payments
$217.11
Companies
16
Transactions
101
Medicare Patients
7,004
Medicare Billing
$445,205
Payment Breakdown by Category
Food & Beverage$2,578 (99.2%)
Education$20.52 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,578 | 99 | 99.2% |
| Education | $20.52 | 2 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $752.73 | 24 | $0 (2024) |
| Novo Nordisk Inc | $689.46 | 15 | $0 (2024) |
| Amarin Pharma Inc. | $255.51 | 4 | $0 (2017) |
| ABBVIE INC. | $250.20 | 22 | $0 (2024) |
| IBSA Pharma Inc. | $171.14 | 14 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $123.51 | 1 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $76.56 | 6 | $0 (2020) |
| ABIOMED | $74.95 | 2 | $0 (2023) |
| GlaxoSmithKline, LLC. | $61.32 | 4 | $0 (2023) |
| Amgen Inc. | $29.87 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $217.11 | 5 | Novo Nordisk Inc ($140.00) |
| 2023 | $524.17 | 10 | AstraZeneca Pharmaceuticals LP ($258.69) |
| 2022 | $222.94 | 9 | Novo Nordisk Inc ($135.98) |
| 2021 | $290.80 | 23 | AstraZeneca Pharmaceuticals LP ($126.24) |
| 2020 | $242.81 | 8 | AstraZeneca Pharmaceuticals LP ($179.04) |
| 2019 | $434.07 | 20 | Novo Nordisk Inc ($254.94) |
| 2018 | $178.89 | 14 | AstraZeneca Pharmaceuticals LP ($84.84) |
| 2017 | $487.45 | 12 | Amarin Pharma Inc. ($255.51) |
All Payment Transactions
101 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $8.28 | General |
| 10/01/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.88 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/19/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $111.43 | General |
| Category: Obesity | ||||||
| 08/21/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $20.29 | General |
| 06/13/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $61.23 | General |
| Category: NEUROSCIENCE | ||||||
| 09/28/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $124.09 | General |
| Category: Respiratory | ||||||
| 07/21/2023 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $15.53 | General |
| Category: RESPIRATORY | ||||||
| 06/13/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), AREXVY | Food and Beverage | In-kind items and services | $14.03 | General |
| Category: VACCINES | ||||||
| 06/02/2023 | ABIOMED | Impella (Device) | Food and Beverage | In-kind items and services | $49.57 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/02/2023 | ABIOMED | Impella (Device) | Food and Beverage | In-kind items and services | $25.38 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/09/2023 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $131.90 | General |
| Category: Obesity | ||||||
| 05/04/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $112.49 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/21/2023 | Novo Nordisk Inc | Rybelsus (Drug) | Food and Beverage | In-kind items and services | $13.97 | General |
| Category: Diabetes | ||||||
| 02/15/2023 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Food and Beverage | In-kind items and services | $15.10 | General |
| Category: VACCINES | ||||||
| 01/03/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug), FARXIGA | Food and Beverage | In-kind items and services | $22.11 | General |
| Category: Respiratory | ||||||
| 11/15/2022 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Food and Beverage | In-kind items and services | $16.66 | General |
| Category: VACCINES | ||||||
| 10/18/2022 | Novo Nordisk Inc | Rybelsus (Drug) | Food and Beverage | In-kind items and services | $6.04 | General |
| Category: Diabetes | ||||||
| 09/30/2022 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $10.92 | General |
| Category: Obesity | ||||||
| 09/22/2022 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $119.02 | General |
| Category: Obesity | ||||||
| 08/30/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.58 | General |
| Category: NEUROSCIENCE | ||||||
| 08/12/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.01 | General |
| Category: NEUROSCIENCE | ||||||
| 06/03/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.08 | General |
| Category: NEUROSCIENCE | ||||||
| 05/03/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.84 | General |
| Category: NEUROSCIENCE | ||||||
| 01/14/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.79 | General |
| Category: NEUROSCIENCE | ||||||
| 11/19/2021 | AbbVie Inc. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $14.25 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 1,631 | 1,922 | $281,887 | $114,406 |
| 2022 | 16 | 1,646 | 1,895 | $267,500 | $77,404 |
| 2021 | 18 | 1,971 | 2,260 | $299,580 | $141,700 |
| 2020 | 19 | 1,756 | 2,025 | $259,466 | $111,694 |
Total Patients
7,004
Total Services
8,102
Medicare Billing
$445,205
Procedure Codes
67
All Medicare Procedures & Services
67 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 312 | 506 | $106,420 | $46,723 | 43.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 200 | 277 | $39,385 | $17,040 | 43.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 107 | 107 | $26,750 | $14,455 | 54.0% |
| 96132 | Evaluation of neuropsychological test, first hour | Office | 2023 | 126 | 128 | $26,075 | $12,451 | 47.8% |
| 92552 | Test for hearing various pitches using earphone | Office | 2023 | 182 | 183 | $21,315 | $5,292 | 24.8% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 195 | 196 | $23,292 | $4,192 | 18.0% |
| 96138 | Administration of psychological or neuropsychological test by technician, first 30 minutes | Office | 2023 | 126 | 128 | $11,132 | $3,833 | 34.4% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 34 | 34 | $2,890 | $2,578 | 89.2% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 12 | 13 | $4,875 | $2,228 | 45.7% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 109 | 109 | $2,725 | $2,157 | 79.2% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 156 | 166 | $14,530 | $1,795 | 12.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 35 | 35 | $1,680 | $1,189 | 70.8% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 11 | 11 | $528.00 | $373.67 | 70.8% |
| 81002 | Urinalysis, manual test | Office | 2023 | 26 | 29 | $290.00 | $98.89 | 34.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 271 | 430 | $87,745 | $20,121 | 22.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 212 | 295 | $41,175 | $13,052 | 31.7% |
| 96132 | Evaluation of neuropsychological test, first hour | Office | 2022 | 99 | 100 | $18,412 | $9,435 | 51.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 157 | 157 | $39,250 | $7,558 | 19.3% |
| 92552 | Test for hearing various pitches using earphone | Office | 2022 | 159 | 159 | $18,225 | $4,563 | 25.0% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2022 | 178 | 178 | $20,470 | $4,016 | 19.6% |
| 90670 | Pneumococcal vaccine, 13-valent | Office | 2022 | 13 | 13 | $3,430 | $3,237 | 94.4% |
| G0444 | Annual depression screening, 15 minutes | Office | 2022 | 157 | 157 | $3,925 | $3,150 | 80.2% |
| 96138 | Administration of psychological or neuropsychological test by technician, first 30 minutes | Office | 2022 | 99 | 100 | $7,714 | $3,074 | 39.9% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 40 | 40 | $3,400 | $2,806 | 82.5% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 147 | 150 | $12,750 | $1,708 | 13.4% |
About Dr. Lin Chou, M.D
Dr. Lin Chou, M.D is a Internal Medicine healthcare provider based in Hillsborough, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1083705560.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lin Chou, M.D has received a total of $2,598 in payments from pharmaceutical and medical device companies, with $217.11 received in 2024. These payments were reported across 101 transactions from 16 companies. The most common payment nature is "Food and Beverage" ($2,578).
As a Medicare-enrolled provider, Chou has provided services to 7,004 Medicare beneficiaries, totaling 8,102 services with total Medicare billing of $445,205. Data is available for 4 years (2020–2023), covering 67 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Hillsborough, NJ
- Active Since 09/27/2006
- Last Updated 07/08/2007
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1083705560
Products in Payments
- FARXIGA (Drug) $606.53
- Saxenda (Drug) $382.42
- Vascepa (Drug) $255.51
- Wegovy (Drug) $243.33
- Tirosint (Drug) $159.87
- BREZTRI (Drug) $146.20
- JARDIANCE (Drug) $123.51
- VRAYLAR (Drug) $92.66
- UBRELVY (Drug) $82.06
- JANUVIA (Drug) $76.56
- QULIPTA (Drug) $75.48
- Impella (Device) $74.95
- SHINGRIX (Biological) $45.79
- INJECTAFER (Drug) $28.10
- XARELTO (Drug) $25.69
- Rybelsus (Drug) $20.01
- Trintellix (Drug) $17.85
- AREXVY (Drug) $15.53
- Ozempic (Drug) $15.13
- Aimovig (Biological) $14.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Hillsborough
Bhavi Patel, M.d, M.D
Internal Medicine — Payments: $5,647
Internal Medicine $5,647
Nazar Raoof, Md, MD
Internal Medicine — Payments: $4,703
Internal Medicine $4,703
Dr. Natalia Raoof, M.d, M.D
Internal Medicine — Payments: $1,579
Internal Medicine $1,579
Laura Riley, M.d, M.D
Internal Medicine — Payments: $1,513
Internal Medicine $1,513
Dr. Rosario Manalo, Md, MD
Internal Medicine — Payments: $1,368
Internal Medicine $1,368
Ranjana Thakur, Md, MD
Internal Medicine — Payments: $387.04
Internal Medicine $387.04